-
Net Sales are expected to increase by 26.8 percent Y-o-Y (down 9.7 percent Q-o-Q) to Rs 547.6 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 16.1 percent Y-o-Y (down 11.8 percent Q-o-Q) to Rs. 327.9 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 14.8 percent Y-o-Y (up 8.7 percent Q-o-Q) to Rs. 364.5 crore, according to Kotak.
-
Net Sales are expected to increase by 14 percent Y-o-Y (up 10.7 percent Q-o-Q) to Rs. 333.2 crore, according to Kotak.
-
Net Sales are expected to increase by 15 percent Y-o-Y (up 11.6 percent Q-o-Q) to Rs. 336.1 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 15.3 percent Y-o-Y (up 5.2 percent Q-o-Q) to Rs. 307.7 crore, according to Kotak.
-
Net Sales are expected to increase by 30.2 percent Y-o-Y (up 18.8 percent Q-o-Q) to Rs. 347.4 crore, according to Prabhudas Lilladher.
-
Brokerages remain mixed on Dr Lal PathLabs performance for the September quarter, with Morgan Stanley maintaining its underweight call on the stock, citing a miss on estimates and valuation issues.
-
Net Sales are expected to increase by 16 percent Y-o-Y (up 8.4 percent Q-o-Q) to Rs. 289.2 crore, according to Kotak.
-
Net Sales are expected to increase by 18.2 percent Y-o-Y to Rs. 260 crore, according to Edelweiss.
-
Dr Lal Pathlabs' revenue growth was aided by a low base in Q3 while volume growth momentum continues. The street is a bit concerned about pricing pressure in an industry that has become so competitive now. In an interview to CNBC-TV18, Om Manchanda, CEO of Dr Lal Pathlabs discussed the company's Q3 performance.
-
The company continues to remain highly competitive right across all segments of market ranging from preventive to illness and even to predictive going into the future, said Dilip Bidani, CFO, Dr. Lal PathLabs.
-
Net Sales are expected to increase by 6.4 percent Y-o-Y (up 11.9 percent Q-o-Q) to Rs. 278.9 crore, according to Kotak.
-
In an interview to CNBC-TV18, Doctor Om Manchanda, CEO of Dr Lal Pathlabs spoke about the results and his outlook for the company.
-
High competitive pressures hamper volume growth this quarter. In an interview to CNBC-TV18, Dilip Bidani, CFO of Dr Lal PathLabs spoke about the results and his outlook for the company.
-
Net Sales are expected to increase by 10.8 percent Q-o-Q (up 16.3 percent Y-o-Y) to Rs 229.9 crore, according to ICICI Securities. Dr. Lal Pathlabs to report net profit at 40.4 crore up 30.8% quarter-on-quarter.
-
Dr Lal Pathlabs' Kolkata labs will start operation by the second half of next year and company‘s central lab will come up by September 2017.
-
Net Sales are expected to decrease by 13.3 percent Q-o-Q (up 20.5 percent Y-o-Y) to Rs 227.2 crore, according to ICICI Securities.
-
It has been a fairly good quarter on account of the seasonal fevers, said Dilip Bidani, CFO, Dr Lal PathLabs in an interview with CNBC-TV18.
-
The current spurt in diagnostic tests on dengue and chikungunya in areas like New Delhi will help Dr Lal PathLabs post good Q2 volumes, says Om Manchanda, Chief Executive of the healthcare firm.
-
The quarter growth has been in-line with expectations, says Om Manchanda, CEO of Dr Lal PathLabs adding that some operational expenses will be seen in the next nine months.
-
Dilip Bidani, CFO of Dr Lal PathLabs expects margins to dilute by 200-300 bps in coming two to three years, but says that growth will be better than the expected industry growth of 16-17 percent in FY17.
-
Om Manchanda, CEO, Dr Lal Pathlabs, says the company's growth of 21 percent this quarter was in line with expectation and was mainly driven by volumes.
